BTG1 inhibits breast cancer cell growth through induction of cell cycle arrest and apoptosis

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2137-2144

  Zhu, Ran ^a   Zou, Shi Tao ^b   Wan, Jian Mei ^a   Li, Wei ^c   Li, Xin Li ^a   Zhu, Wei ^a  

^a SOOCHOW UNIVERSITY   (China)

^b Wuxi Fourth People's Hospital   (China)

^c THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Apoptosis; Breast cancer; BTG1; Cell cycle; Nude mice

Indexed keywords

CASPASE 3; CYCLIN B1; CYCLIN D1; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BTG1 GENE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CASPASE 3; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MCF-7 CELLS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84885069923     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2697     Document Type: Article

References (28)

1. Parrella P: Epigenetic signatures in breast cancer: clinical perspective. Breast Care 5: 66-73, 2010.
2. Rouault JP, Rimokh R, Tessa C, Paranhos G, Ffrench M, Duret L, Garoccio M, Germain D, Samarut J and Magaud JP: BTG1, a member of a new family of antiproliferative genes. EMBO J 11: 1663-1670, 1992.
3. Berthet C, Guehenneux F, Revol V, Samarut C, Lukaszewicz A, Dehay C, Dumontet C, Magaud JP and Rouault JP: Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. Genes Cells 7: 29-39, 2002.
4. Matsuda S, Rouault J, Magaud J and Berthet C: In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett 497: 67-72, 2001.
5. Bakker WJ, Blazquez-Domingo M, Kolbus A, Besooyen J, Steinlein P, Beug H, Coffer PJ, Lowenberg B, von Lindern M and van Dijk TB: FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1. J Cell Biol 164: 175-184, 2004
6. Hata K, Nishijima K and Mizuguchi J: Role for Btg1 and Btg2 in growth arrest of WEHI-231 cells through arginine methylation following membrane immunoglobulin engagement. Exp Cell Res 313: 2356-2366, 2007.
7. van Galen JC, Kuiper RP, van Emst L, Levers M, Tijchon E, Scheijen B, Waanders E, van Reijmersdal SV, Gilissen C, van Kessel AG, et al: BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. Blood 115: 4810-4819, 2010.
8. Prevot D, Voeltzel T, Birot AM, Morel AP, Rostan MC, Magaud JP and Corbo L: The leukemia-associated protein Btg1 and the p53-regulated protein Btg2 interact with the homeoprotein Hoxb9 and enhance its transcriptional activation. J Biol Chem 275: 147-153, 2000.
9. Prevot D, Morel AP, Voeltzel T, Rostan MC, Rimokh R, Magaud JP and Corbo L: Relationships of the antiproliferative proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex: involvement in estrogen receptor alpha signaling pathway. J Biol Chem 276: 9640-9648, 2001.
10. Busson M, Carazo A, Seyer P, Grandemange S, Casas F, Pessemesse L, Rouault JP, Wrutniak-Cabello C and Cabello G: Coactivation of nuclear receptors and myogenic factors induces the major BTG1 influence on muscle differentiation. Oncogene 24: 1698-1710, 2005.
11. Corjay MH, Kearney MA, Munzer DA, Diamond SM and Stoltenborg JK: Antiproliferative gene BTG1 is highly expressed in apoptotic cells in macrophage-rich areas of advanced lesions in Watanabe heritable hyperlipidemic rabbit and human. Lab Invest 78: 847-858, 1998.
12. Lee H, Cha S, Lee MS, Cho GJ, Choi WS and Suk K: Role of antiproliferative B cell translocation gene-1 as an apoptotic sensitizer in activation-induced cell death of brain microglia. J Immunol 171: 5802-5811, 2003.
13. Rodier A, Marchal-Victorion S, Rochard P, Casas F, Cassar-Malek I, Rouault JP, Magaud JP, Mason DY, Wrutniak C and Cabello G: BTG1: a triiodothyronine target involved in the myogenic influence of the hormone. Exp Cell Res 249: 337-348, 1999.
14. Cho JW, Kim JJ, Park SG, Lee DH, Lee SC, Kim HJ, Park BC and Cho S: Identification of B-cell translocation gene 1 as a biomarker for monitoring the remission of acute myeloid leukemia. Proteomics 4: 3456-3463, 2004.
15. Farhana L, Dawson M, Rishi AK, Zhang Y, Van Buren E, Trivedi C, Reichert U, Fang G, Kirschner MW and Fontana JA: Cyclin B and E2F-1 expression in prostate carcinoma cells treated with the novel retinoid CD437 are regulated by the ubiquitin-mediated pathway. Cancer Res 62: 3842-3849, 2002.
16. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK and Sutherland RL: Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13: 3577-3587, 1993.
17. Hwang A, McKenna WG and Muschel RJ: Cell cycle-dependent usage of transcriptional start sites. A novel mechanism for regulation of cyclin B1. J Biol Chem 273: 31505-31509, 1998.
18. Hershko A: Mechanisms and regulation of the degradation of cyclin B. Philos Trans R Soc Lond B Biol Sci 354: 1571-1576, 1999.
19. Vorlaufer E and Peters JM: Regulation of the cyclin B degradation system by an inhibitor of mitotic proteolysis. Mol Biol Cell 9: 1817-1831, 1998.
20. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF and Sherr CJ: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7: 1559-1571, 1993.
21. Ewen ME and Lamb J: The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 10: 158-162, 2004.
22. Arnold A and Papanikolaou A: Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23: 4215-4224, 2005.
23. Nahta R and Esteva FJ: Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer. Semin Oncol 30: 143-149, 2003.
24. Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194, 2005.
25. Kymionis GD, Dimitrakakis CE, Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G, Keramopoulos A and Michalas S: Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? J Surg Res 99: 161-168, 2001.
26. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1-16, 1997.
27. Thornberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998.
28. Kuida K, Zheng TS, Na S, Kuan C, Yang D, Karasuyama H, Rakic P and Flavell RA: Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 384: 368-372, 1996.